{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:04:45Z","timestamp":1778717085593,"version":"3.51.4"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005627","name":"Thrasher Research Fund","doi-asserted-by":"crossref","award":["ID#12917"],"award-info":[{"award-number":["ID#12917"]}],"id":[{"id":"10.13039\/100005627","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.cct.2019.01.009","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T12:07:32Z","timestamp":1547640452000},"page":"27-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods"],"prefix":"10.1016","volume":"78","author":[{"given":"Monica","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn V.","family":"Blake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward B.","family":"Mougey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Franciosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Jobayer","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan","family":"Cobbaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard M.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2019.01.009_bb0005","first-page":"1","article-title":"Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010","volume":"94","author":"Akinbami","year":"2012","journal-title":"NCHS Data Brief"},{"issue":"2","key":"10.1016\/j.cct.2019.01.009_bb0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1542\/peds.2004-0678","article-title":"Overweight, obesity, and health-related quality of life among adolescents: the National Longitudinal Study of Adolescent Health","volume":"115","author":"Swallen","year":"2005","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.cct.2019.01.009_bb0015","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jaci.2014.08.029","article-title":"Overweight children report qualitatively distinct asthma symptoms: Analysis of validated symptom measures","volume":"135","author":"Lang","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.cct.2019.01.009_bb0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00431-017-3051-4","article-title":"Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment","volume":"177","author":"Franciosi","year":"2018","journal-title":"Eur. J. Pediatr."},{"issue":"6","key":"10.1016\/j.cct.2019.01.009_bb0025","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1152\/japplphysiol.00572.2009","article-title":"Acid aspiration-induced airways hyperresponsiveness in mice","volume":"107","author":"Allen","year":"2009","journal-title":"J. Appl. Physiol."},{"issue":"1","key":"10.1016\/j.cct.2019.01.009_bb0030","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1152\/ajpregu.00394.2007","article-title":"Airway responses to esophageal acidification","volume":"294","author":"Lang","year":"2008","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0035","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1152\/jappl.1997.82.3.738","article-title":"Esophageal stimulation by hydrochloric acid causes neurogenic inflammation in the airways in guinea pigs","volume":"82","author":"Hamamoto","year":"1997","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.cct.2019.01.009_bb0040","series-title":"Pulmonary Responses to Tracheal or Esophageal Acidification in Guinea Pigs With Airway Inflammation","author":"Lopes","year":"2018"},{"issue":"12","key":"10.1016\/j.cct.2019.01.009_bb0045","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/gut.2007.122465","article-title":"The association between gastro-oesophageal reflux disease and asthma: a systematic review","volume":"56","author":"Havemann","year":"2007","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cct.2019.01.009_bb0050","doi-asserted-by":"crossref","first-page":"e925","DOI":"10.1542\/peds.2009-2382","article-title":"Gastroesophageal reflux and asthma in children: a systematic review","volume":"125","author":"Thakkar","year":"2010","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.cct.2019.01.009_bb0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0016-5085(90)91231-T","article-title":"Acid-induced esophagobronchial-cardiac reflexes in humans","volume":"99","author":"Wright","year":"1990","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cct.2019.01.009_bb0060","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1378\/chest.118.6.1553","article-title":"Effects of esophageal acid perfusion on airway hyperresponsiveness in patients with bronchial asthma","volume":"118","author":"Wu","year":"2000","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.cct.2019.01.009_bb0065","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/dote.12108","article-title":"Experimental study for the mechanism of gastroesophageal-reflux-associated asthma","volume":"27","author":"Zhu","year":"2014","journal-title":"Dis. Esophagus"},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0070","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1378\/chest.106.3.731","article-title":"Gastroesophageal reflux-induced bronchoconstriction. An intraesophageal acid infusion study using state-of-the-art technology","volume":"106","author":"Schan","year":"1994","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.cct.2019.01.009_bb0075","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1378\/chest.108.5.1220","article-title":"Gastroesophageal reflux-induced bronchoconstriction. Is microaspiration a factor?","volume":"108","author":"Harding","year":"1995","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0080","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1378\/chest.90.3.358","article-title":"Pulmonary function and acid application in the esophagus","volume":"90","author":"Andersen","year":"1986","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.cct.2019.01.009_bb0085","first-page":"431","article-title":"The role of the vague nerve in airway narrowing caused by intraesophageal hydrochloric acid provocation and esophageal distention","volume":"47","author":"Mansfield","year":"1981","journal-title":"Ann. Allergy"},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0090","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1378\/chest.115.3.654","article-title":"24-h esophageal pH testing in asthmatics: respiratory symptom correlation with esophageal acid events","volume":"115","author":"Harding","year":"1999","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.cct.2019.01.009_bb0095","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00464-005-0329-9","article-title":"Long-term outcomes of laparoscopic antireflux surgery for gastroesophageal reflux disease (GERD)-related airway disorder","volume":"20","author":"Kaufman","year":"2006","journal-title":"Surg. Endosc."},{"issue":"5","key":"10.1016\/j.cct.2019.01.009_bb0100","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1159\/000064021","article-title":"Gastroesophageal reflux and bronchial responsiveness: correlation and the effect of fundoplication","volume":"69","author":"Kiljander","year":"2002","journal-title":"Respiration"},{"issue":"6","key":"10.1016\/j.cct.2019.01.009_bb0105","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1378\/chest.99.6.1330","article-title":"Medical and surgical treatment of nonallergic asthma associated with gastroesophageal reflux","volume":"99","author":"Larrain","year":"1991","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.cct.2019.01.009_bb0110","first-page":"987","article-title":"Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies","volume":"98","author":"Sontag","year":"2003","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.cct.2019.01.009_bb0115","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1378\/chest.123.4.1008","article-title":"Role of gastroesophageal reflux in older children with persistent asthma","volume":"123","author":"Khoshoo","year":"2003","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.cct.2019.01.009_bb0120","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/adc.2004.068890","article-title":"Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease","volume":"90","author":"Stordal","year":"2005","journal-title":"Arch. Dis. Child."},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0125","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.rmed.2005.07.006","article-title":"Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease","volume":"100","author":"Yuksel","year":"2006","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MPG.0b013e31802fe89c","article-title":"Effect of antireflux treatment on asthma exacerbations in nonatopic children","volume":"44","author":"Khoshoo","year":"2007","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"11","key":"10.1016\/j.cct.2019.01.009_bb0135","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/ppul.21094","article-title":"Bronchial hyperreactivity in non-atopic children with asthma and reflux: effect of anti-reflux treatment","volume":"44","author":"Khoshoo","year":"2009","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.cct.2019.01.009_bb0140","doi-asserted-by":"crossref","first-page":"967460","DOI":"10.1155\/2011\/967460","article-title":"Induced sputum substance p in children with difficult-to-treat bronchial asthma and gastroesophageal reflux: effect of esomeprazole therapy","volume":"2011","author":"Bediwy","year":"2011","journal-title":"Int. J. Pediatr."},{"issue":"4","key":"10.1016\/j.cct.2019.01.009_bb0145","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/jama.2011.2035","article-title":"Lansoprazole for children with poorly controlled asthma: a randomized controlled trial","volume":"307","author":"Writing Committee for the American Lung Association Asthma Clinical Research, C","year":"2012","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.cct.2019.01.009_bb0150","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2133\/dmpk.20.153","article-title":"Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies","volume":"20","author":"Furuta","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.cct.2019.01.009_bb0160","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2217\/pgs.11.4","article-title":"Update on the pharmacogenomics of proton pump inhibitors","volume":"12","author":"Hagymasi","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.cct.2019.01.009_bb0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/gim.0b013e3182329870","article-title":"Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory","volume":"14","author":"Strom","year":"2012","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0170","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000028398","article-title":"The CYP2C19 enzyme polymorphism","volume":"61","author":"Wedlund","year":"2000","journal-title":"Pharmacology"},{"issue":"11","key":"10.1016\/j.cct.2019.01.009_bb0175","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2217\/pgs.14.103","article-title":"Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs","volume":"15","author":"Lima","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.cct.2019.01.009_bb0180","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/gim.0b013e3182329870","article-title":"Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory","volume":"14","author":"Strom","year":"2011","journal-title":"Genet. Med."},{"issue":"4","key":"10.1016\/j.cct.2019.01.009_bb0185","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/ajrccm\/147.4.832","article-title":"Measuring quality of life in asthma","volume":"147","author":"Juniper","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.cct.2019.01.009_bb0190","series-title":"Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (Full Report 2007)","first-page":"1","author":"NAEPP","year":"2007"},{"issue":"2","key":"10.1016\/j.cct.2019.01.009_bb0195","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/01.mpg.0000172885.77795.0f","article-title":"Age-specific questionnaires distinguish GERD symptom frequency and severity in infants and young children: development and initial validation","volume":"41","author":"Deal","year":"2005","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.cct.2019.01.009_bb0200","series-title":"North American Society for Pediatric Gastroenterology, Hepatology and Nutrition","author":"GERD in Children and Adolescents","year":"2018"},{"issue":"10","key":"10.1016\/j.cct.2019.01.009_bb0205","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa1710988","article-title":"Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations","volume":"378","author":"Jackson","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.cct.2019.01.009_bb0210","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa070013","article-title":"Randomized comparison of strategies for reducing treatment in mild persistent asthma","volume":"356","author":"American Lung Association Asthma Clinical Research, C","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cct.2019.01.009_bb0215","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1378\/chest.114.4.998","article-title":"Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index","volume":"114","author":"Revicki","year":"1998","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0220","first-page":"1107","article-title":"Update. American Thoracic Society","volume":"152","author":"Standardization of Spirometry, 1995","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0225","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/thoraxjnl-2015-207662","article-title":"Gastro-oesophageal reflux and worse asthma control in obese children: a case of symptom misattribution?","volume":"71","author":"Lang","year":"2016","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.cct.2019.01.009_bb0230","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jpba.2008.08.034","article-title":"Simultaneous determination of lansoprazole and its metabolites 5\u2032-hydroxy lansoprazole and lansoprazole sulphone in human plasma by LC-MS\/MS: application to a pharmacokinetic study in healthy volunteers","volume":"48","author":"Song","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"11","key":"10.1016\/j.cct.2019.01.009_bb0235","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.3109\/00498254.2012.687119","article-title":"Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects","volume":"42","author":"Zhang","year":"2012","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.cct.2019.01.009_bb0240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF03190639","article-title":"Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method","volume":"31","author":"Chen","year":"2006","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"11","key":"10.1016\/j.cct.2019.01.009_bb0245","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00228-010-0892-4","article-title":"Effect of CYP2C19 genotypes on the pharmacokinetic\/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers","volume":"66","author":"Sheng","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0250","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/00912700122010069","article-title":"Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model","volume":"41","author":"Puchalski","year":"2001","journal-title":"J. Clin. Pharmacol."},{"issue":"19","key":"10.1016\/j.cct.2019.01.009_bb0255","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1001\/jama.2015.13896","article-title":"Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial","volume":"314","author":"Bacharier","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2019.01.009_bb0260","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jviromet.2015.11.020","article-title":"Comparative analytical evaluation of the respiratory TaqMan Array Card with real-time PCR and commercial multi-pathogen assays","volume":"228","author":"Harvey","year":"2016","journal-title":"J. Virol. Methods"},{"issue":"4","key":"10.1016\/j.cct.2019.01.009_bb0265","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2133\/dmpk.20.300","article-title":"Genetic variations and haplotypes of CYP2C19 in a Japanese population","volume":"20","author":"Fukushima-Uesaka","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.cct.2019.01.009_bb0270","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2174\/138920012803341393","article-title":"The influence of CYP2C19 genetic polymorphism on the pharmacokinetics\/\u2212 pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments","volume":"13","author":"Serrano","year":"2012","journal-title":"Curr. Drug Metab."},{"issue":"10","key":"10.1016\/j.cct.2019.01.009_bb0275","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00228-008-0538-y","article-title":"Proton pump inhibitors: an update of their clinical use and pharmacokinetics","volume":"64","author":"Shi","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.cct.2019.01.009_bb0280","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1365-2036.2000.00788.x","article-title":"Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors","volume":"14","author":"Stedman","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.cct.2019.01.009_bb0285","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF03262211","article-title":"Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19","volume":"16","author":"Furuta","year":"2012","journal-title":"Mol. Diagn. Ther."},{"issue":"2","key":"10.1016\/j.cct.2019.01.009_bb0290","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/phgs.5.2.181.27483","article-title":"Pharmacogenomics of proton pump inhibitors","volume":"5","author":"Furuta","year":"2004","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.cct.2019.01.009_bb0295","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1067\/mcp.2001.119721","article-title":"Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19","volume":"70","author":"Furuta","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.cct.2019.01.009_bb0300","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00228-011-1151-z","article-title":"Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood","volume":"68","author":"Gumus","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.cct.2019.01.009_bb0305","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1124\/dmd.109.030601","article-title":"Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect","volume":"38","author":"Kearns","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.cct.2019.01.009_bb0310","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00228-010-0811-8","article-title":"Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD)","volume":"66","author":"Ward","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0315","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/0091270010366146","article-title":"Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years","volume":"51","author":"Knebel","year":"2011","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0320","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jpeds.2013.03.017","article-title":"Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children","volume":"163","author":"Lima","year":"2013","journal-title":"J. Pediatr."},{"issue":"7","key":"10.1016\/j.cct.2019.01.009_bb0325","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/ajg.2012.179","article-title":"Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis","volume":"107","author":"Janarthanan","year":"2012","journal-title":"Am. J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.cct.2019.01.009_bb0330","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ajg.2012.108","article-title":"Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis","volume":"107","author":"Kwok","year":"2012","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.cct.2019.01.009_bb0335","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1586\/17512433.2013.811206","article-title":"Perils and pitfalls of long-term effects of proton pump inhibitors","volume":"6","author":"Wilhelm","year":"2013","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.cct.2019.01.009_bb0340","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1503\/cmaj.092129","article-title":"Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis","volume":"183","author":"Eom","year":"2011","journal-title":"CMAJ"},{"issue":"20","key":"10.1016\/j.cct.2019.01.009_bb0345","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.2009.722","article-title":"Acid-suppressive medication use and the risk for hospital-acquired pneumonia","volume":"301","author":"Herzig","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.cct.2019.01.009_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128004","article-title":"Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis","volume":"10","author":"Lambert","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.cct.2019.01.009_bb0355","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1513\/AnnalsATS.201408-391OC","article-title":"Lansoprazole is associated with worsening asthma control in children with the CYP2C19 poor metabolizer phenotype","volume":"12","author":"Lang","year":"2015","journal-title":"Ann. Am. Thorac. Soc."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714418306529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714418306529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T13:26:14Z","timestamp":1552569974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714418306529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":71,"alternative-id":["S1551714418306529"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2019.01.009","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2019.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}